#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Primary liver cancer is the sixth most prevalent cancer and the second leading cause of cancer mortality worldwide .
2-1	16-23	Primary	abstract[3]	new[3]	coref	2-5[4_3]
2-2	24-29	liver	object|abstract[3]	new|new[3]	coref	3-5
2-3	30-36	cancer	abstract[3]	new[3]	_	_
2-4	37-39	is	_	_	_	_
2-5	40-43	the	abstract[4]	giv[4]	coref	3-1[9_4]
2-6	44-49	sixth	abstract[4]	giv[4]	_	_
2-7	50-54	most	abstract[4]	giv[4]	_	_
2-8	55-64	prevalent	abstract[4]	giv[4]	_	_
2-9	65-71	cancer	abstract[4]	giv[4]	_	_
2-10	72-75	and	abstract[4]	giv[4]	_	_
2-11	76-79	the	abstract[4]|abstract[5]	giv[4]|new[5]	_	_
2-12	80-86	second	abstract[4]|abstract[5]	giv[4]|new[5]	_	_
2-13	87-94	leading	abstract[4]|abstract[5]	giv[4]|new[5]	_	_
2-14	95-100	cause	abstract[4]|abstract[5]	giv[4]|new[5]	_	_
2-15	101-103	of	abstract[4]|abstract[5]	giv[4]|new[5]	_	_
2-16	104-110	cancer	abstract[4]|abstract[5]|object[7]	giv[4]|new[5]|new[7]	_	_
2-17	111-120	mortality	abstract[4]|abstract[5]|abstract|object[7]	giv[4]|new[5]|new|new[7]	_	_
2-18	121-130	worldwide	abstract[4]|abstract[5]|object[7]	giv[4]|new[5]|new[7]	_	_
2-19	131-132	.	_	_	_	_

#Text=The most common primary liver cancer is hepatocellular carcinoma ( HCC ) , which accounts for >85 % of all cases .
3-1	133-136	The	abstract[9]	giv[9]	coref	3-8[10_9]
3-2	137-141	most	abstract[9]	giv[9]	_	_
3-3	142-148	common	abstract[9]	giv[9]	_	_
3-4	149-156	primary	abstract[9]	giv[9]	_	_
3-5	157-162	liver	object|abstract[9]	giv|giv[9]	coref	5-11
3-6	163-169	cancer	abstract[9]	giv[9]	_	_
3-7	170-172	is	_	_	_	_
3-8	173-187	hepatocellular	abstract[10]	giv[10]	appos	3-11[0_10]
3-9	188-197	carcinoma	abstract[10]	giv[10]	_	_
3-10	198-199	(	_	_	_	_
3-11	200-203	HCC	abstract	giv	coref	4-1
3-12	204-205	)	_	_	_	_
3-13	206-207	,	_	_	_	_
3-14	208-213	which	_	_	_	_
3-15	214-222	accounts	_	_	_	_
3-16	223-226	for	_	_	_	_
3-17	227-230	>85	quantity[12]	new[12]	coref	6-9[32_12]
3-18	231-232	%	quantity[12]	new[12]	_	_
3-19	233-235	of	quantity[12]	new[12]	_	_
3-20	236-239	all	quantity[12]|abstract[13]	new[12]|new[13]	_	_
3-21	240-245	cases	quantity[12]|abstract[13]	new[12]|new[13]	_	_
3-22	246-247	.	_	_	_	_

#Text=HCC predominantly arises in the setting of cirrhosis associated with hepatitis B and C virus infections , alcohol abuse , non-alcoholic steatohepatitis and metabolic diseases .
4-1	248-251	HCC	abstract	giv	coref	5-2
4-2	252-265	predominantly	_	_	_	_
4-3	266-272	arises	_	_	_	_
4-4	273-275	in	_	_	_	_
4-5	276-279	the	abstract[15]	new[15]	_	_
4-6	280-287	setting	abstract[15]	new[15]	_	_
4-7	288-290	of	abstract[15]	new[15]	_	_
4-8	291-300	cirrhosis	abstract[15]|abstract	new[15]|new	_	_
4-9	301-311	associated	_	_	_	_
4-10	312-316	with	_	_	_	_
4-11	317-326	hepatitis	abstract|place[18]	new|new[18]	_	_
4-12	327-328	B	place[18]	new[18]	_	_
4-13	329-332	and	_	_	_	_
4-14	333-334	C	_	_	_	_
4-15	335-340	virus	abstract|event[20]	new|new[20]	_	_
4-16	341-351	infections	event[20]	new[20]	_	_
4-17	352-353	,	_	_	_	_
4-18	354-361	alcohol	event[21]	new[21]	_	_
4-19	362-367	abuse	event[21]	new[21]	_	_
4-20	368-369	,	_	_	_	_
4-21	370-383	non-alcoholic	abstract[22]	new[22]	_	_
4-22	384-399	steatohepatitis	abstract[22]	new[22]	_	_
4-23	400-403	and	_	_	_	_
4-24	404-413	metabolic	abstract[23]	new[23]	_	_
4-25	414-422	diseases	abstract[23]	new[23]	_	_
4-26	423-424	.	_	_	_	_

#Text=Early-stage HCC patients are often subjected to surgical resection and liver transplantation .
5-1	425-436	Early-stage	person[25]	new[25]	coref	7-28[50_25]
5-2	437-440	HCC	abstract|person[25]	giv|new[25]	coref	8-12
5-3	441-449	patients	person[25]	new[25]	_	_
5-4	450-453	are	_	_	_	_
5-5	454-459	often	_	_	_	_
5-6	460-469	subjected	_	_	_	_
5-7	470-472	to	_	_	_	_
5-8	473-481	surgical	event[26]	new[26]	coref	6-7[0_26]
5-9	482-491	resection	event[26]	new[26]	_	_
5-10	492-495	and	_	_	_	_
5-11	496-501	liver	object|event[28]	giv|new[28]	coref|coref|coref|coref	6-15[0_28]|7-37|6-15[0_28]|7-37
5-12	502-517	transplantation	event[28]	new[28]	_	_
5-13	518-519	.	_	_	_	_

#Text=However , 5-year recurrence rates after resection reach >70 % and the efficiency of transplantation is limited by organ shortage and technical issues .
6-1	520-527	However	_	_	_	_
6-2	528-529	,	_	_	_	_
6-3	530-536	5-year	abstract[30]	new[30]	coref	7-9[42_30]
6-4	537-547	recurrence	event|abstract[30]	new|new[30]	_	_
6-5	548-553	rates	abstract[30]	new[30]	_	_
6-6	554-559	after	_	_	_	_
6-7	560-569	resection	event	giv	_	_
6-8	570-575	reach	_	_	_	_
6-9	576-579	>70	quantity[32]|abstract[33]	giv[32]|new[33]	coref|coref|coref|coref	7-15[44_32]|7-15[45_33]|7-15[44_32]|7-15[45_33]
6-10	580-581	%	quantity[32]|abstract[33]	giv[32]|new[33]	_	_
6-11	582-585	and	abstract[33]	new[33]	_	_
6-12	586-589	the	abstract[33]|abstract[34]	new[33]|new[34]	_	_
6-13	590-600	efficiency	abstract[33]|abstract[34]	new[33]|new[34]	_	_
6-14	601-603	of	abstract[33]|abstract[34]	new[33]|new[34]	_	_
6-15	604-619	transplantation	abstract[33]|abstract[34]|event	new[33]|new[34]|giv	_	_
6-16	620-622	is	_	_	_	_
6-17	623-630	limited	_	_	_	_
6-18	631-633	by	_	_	_	_
6-19	634-639	organ	abstract|abstract[37]	new|new[37]	_	_
6-20	640-648	shortage	abstract[37]	new[37]	_	_
6-21	649-652	and	_	_	_	_
6-22	653-662	technical	abstract[38]	new[38]	_	_
6-23	663-669	issues	abstract[38]	new[38]	_	_
6-24	670-671	.	_	_	_	_

#Text=Although local ablation and transarterial chemoembolization respectively confer 5-year survival rates of 50 – 70 % and survival benefit of >6 months , they are confined to patients with single tumors or multinodular tumors with good liver reserve .
7-1	672-680	Although	_	_	_	_
7-2	681-686	local	abstract[39]	new[39]	_	_
7-3	687-695	ablation	abstract[39]	new[39]	_	_
7-4	696-699	and	_	_	_	_
7-5	700-713	transarterial	substance[40]	new[40]	_	_
7-6	714-731	chemoembolization	substance[40]	new[40]	_	_
7-7	732-744	respectively	_	_	_	_
7-8	745-751	confer	_	_	_	_
7-9	752-758	5-year	abstract[42]	giv[42]	_	_
7-10	759-767	survival	event|abstract[42]	new|giv[42]	coref	7-18
7-11	768-773	rates	abstract[42]	giv[42]	_	_
7-12	774-776	of	abstract[42]	giv[42]	_	_
7-13	777-779	50	abstract[42]|quantity	giv[42]|new	_	_
7-14	780-781	–	abstract[42]	giv[42]	_	_
7-15	782-784	70	abstract[42]|quantity[44]|abstract[45]	giv[42]|giv[44]|giv[45]	ana|coref|ana|coref	7-24[0_45]|12-19[97_44]|7-24[0_45]|12-19[97_44]
7-16	785-786	%	abstract[42]|quantity[44]|abstract[45]	giv[42]|giv[44]|giv[45]	_	_
7-17	787-790	and	abstract[42]|abstract[45]	giv[42]|giv[45]	_	_
7-18	791-799	survival	abstract[42]|abstract[45]|event|abstract[47]	giv[42]|giv[45]|giv|new[47]	coref|coref	10-14[72_0]|10-14[72_0]
7-19	800-807	benefit	abstract[42]|abstract[45]|abstract[47]	giv[42]|giv[45]|new[47]	_	_
7-20	808-810	of	abstract[42]|abstract[45]|abstract[47]	giv[42]|giv[45]|new[47]	_	_
7-21	811-813	>6	abstract[42]|abstract[45]|abstract[47]|time[48]	giv[42]|giv[45]|new[47]|new[48]	_	_
7-22	814-820	months	abstract[42]|abstract[45]|abstract[47]|time[48]	giv[42]|giv[45]|new[47]|new[48]	_	_
7-23	821-822	,	_	_	_	_
7-24	823-827	they	abstract	giv	_	_
7-25	828-831	are	_	_	_	_
7-26	832-840	confined	_	_	_	_
7-27	841-843	to	_	_	_	_
7-28	844-852	patients	person[50]	giv[50]	_	_
7-29	853-857	with	person[50]	giv[50]	_	_
7-30	858-864	single	person[50]|object[51]	giv[50]|new[51]	_	_
7-31	865-871	tumors	person[50]|object[51]	giv[50]|new[51]	_	_
7-32	872-874	or	person[50]	giv[50]	_	_
7-33	875-887	multinodular	person[50]|object[52]	giv[50]|new[52]	_	_
7-34	888-894	tumors	person[50]|object[52]	giv[50]|new[52]	_	_
7-35	895-899	with	person[50]|object[52]	giv[50]|new[52]	_	_
7-36	900-904	good	person[50]|object[52]|abstract[54]	giv[50]|new[52]|new[54]	_	_
7-37	905-910	liver	person[50]|object[52]|object|abstract[54]	giv[50]|new[52]|giv|new[54]	_	_
7-38	911-918	reserve	person[50]|object[52]|abstract[54]	giv[50]|new[52]|new[54]	_	_
7-39	919-920	.	_	_	_	_

#Text=Chemotherapy is not routinely used due to the chemoresistant character of HCC .
8-1	921-933	Chemotherapy	abstract	new	_	_
8-2	934-936	is	_	_	_	_
8-3	937-940	not	_	_	_	_
8-4	941-950	routinely	_	_	_	_
8-5	951-955	used	_	_	_	_
8-6	956-959	due	_	_	_	_
8-7	960-962	to	_	_	_	_
8-8	963-966	the	abstract[56]	new[56]	_	_
8-9	967-981	chemoresistant	abstract[56]	new[56]	_	_
8-10	982-991	character	abstract[56]	new[56]	_	_
8-11	992-994	of	abstract[56]	new[56]	_	_
8-12	995-998	HCC	abstract[56]|abstract	new[56]|giv	coref	9-2[58_0]
8-13	999-1000	.	_	_	_	_

#Text=For advanced HCC , sorafenib , a multi-tyrosine kinase inhibitor ( MTKI ) , has been the only approved systemic first-line agent for over a decade , until lenvatinib , another MTKI , recently came into play .
9-1	1001-1004	For	_	_	_	_
9-2	1005-1013	advanced	abstract[58]|abstract[59]	giv[58]|new[59]	ana|coref|ana|coref	10-3[0_59]|11-34[0_58]|10-3[0_59]|11-34[0_58]
9-3	1014-1017	HCC	abstract[58]|abstract[59]	giv[58]|new[59]	_	_
9-4	1018-1019	,	abstract[59]	new[59]	_	_
9-5	1020-1029	sorafenib	abstract[59]|substance	new[59]|new	_	_
9-6	1030-1031	,	_	_	_	_
9-7	1032-1033	a	abstract[62]	new[62]	_	_
9-8	1034-1048	multi-tyrosine	abstract[62]	new[62]	_	_
9-9	1049-1055	kinase	abstract|abstract[62]	new|new[62]	_	_
9-10	1056-1065	inhibitor	abstract[62]	new[62]	_	_
9-11	1066-1067	(	_	_	_	_
9-12	1068-1072	MTKI	object	new	appos	9-31[67_0]
9-13	1073-1074	)	_	_	_	_
9-14	1075-1076	,	_	_	_	_
9-15	1077-1080	has	_	_	_	_
9-16	1081-1085	been	_	_	_	_
9-17	1086-1089	the	person[64]	new[64]	_	_
9-18	1090-1094	only	person[64]	new[64]	_	_
9-19	1095-1103	approved	person[64]	new[64]	_	_
9-20	1104-1112	systemic	person[64]	new[64]	_	_
9-21	1113-1123	first-line	person[64]	new[64]	_	_
9-22	1124-1129	agent	person[64]	new[64]	_	_
9-23	1130-1133	for	person[64]	new[64]	_	_
9-24	1134-1138	over	person[64]	new[64]	_	_
9-25	1139-1140	a	person[64]|time[65]	new[64]|new[65]	_	_
9-26	1141-1147	decade	person[64]|time[65]	new[64]|new[65]	_	_
9-27	1148-1149	,	person[64]	new[64]	_	_
9-28	1150-1155	until	person[64]	new[64]	_	_
9-29	1156-1166	lenvatinib	person[64]|substance	new[64]|new	_	_
9-30	1167-1168	,	_	_	_	_
9-31	1169-1176	another	object[67]	giv[67]	_	_
9-32	1177-1181	MTKI	object[67]	giv[67]	_	_
9-33	1182-1183	,	_	_	_	_
9-34	1184-1192	recently	_	_	_	_
9-35	1193-1197	came	_	_	_	_
9-36	1198-1202	into	_	_	_	_
9-37	1203-1207	play	event	new	_	_
9-38	1208-1209	.	_	_	_	_

#Text=Yet , their clinical efficacy was suboptimal , with only ~3 months of prolonged survival .
10-1	1210-1213	Yet	_	_	_	_
10-2	1214-1215	,	_	_	_	_
10-3	1216-1221	their	abstract|abstract[70]	giv|new[70]	_	_
10-4	1222-1230	clinical	abstract[70]	new[70]	_	_
10-5	1231-1239	efficacy	abstract[70]	new[70]	_	_
10-6	1240-1243	was	_	_	_	_
10-7	1244-1254	suboptimal	_	_	_	_
10-8	1255-1256	,	_	_	_	_
10-9	1257-1261	with	_	_	_	_
10-10	1262-1266	only	time[71]	new[71]	_	_
10-11	1267-1269	~3	time[71]	new[71]	_	_
10-12	1270-1276	months	time[71]	new[71]	_	_
10-13	1277-1279	of	time[71]	new[71]	_	_
10-14	1280-1289	prolonged	time[71]|event[72]	new[71]|giv[72]	coref	12-16[0_72]
10-15	1290-1298	survival	time[71]|event[72]	new[71]|giv[72]	_	_
10-16	1299-1300	.	_	_	_	_

#Text=Second-line treatments include regorafenib and cabozantinib , also MTKIs ; nivolumab and pembrolizumab , immune checkpoint inhibitors targeting programmed death-1 ( PD-1 ) ; and ramucirumab , the first biomarker-driven therapeutics approved for HCC that targets the angiogenic vascular endothelial growth factor receptor ( VEGFR ) , all of which have not been established until the past few years and require further investigations .
11-1	1301-1312	Second-line	abstract[73]	new[73]	_	_
11-2	1313-1323	treatments	abstract[73]	new[73]	_	_
11-3	1324-1331	include	_	_	_	_
11-4	1332-1343	regorafenib	substance	new	_	_
11-5	1344-1347	and	_	_	_	_
11-6	1348-1360	cabozantinib	substance	new	appos	11-9[77_0]
11-7	1361-1362	,	_	_	_	_
11-8	1363-1367	also	_	_	_	_
11-9	1368-1373	MTKIs	object|substance[77]	new|giv[77]	_	_
11-10	1374-1375	;	substance[77]	giv[77]	_	_
11-11	1376-1385	nivolumab	substance[77]	giv[77]	_	_
11-12	1386-1389	and	substance[77]	giv[77]	_	_
11-13	1390-1403	pembrolizumab	substance[77]	giv[77]	_	_
11-14	1404-1405	,	substance[77]	giv[77]	_	_
11-15	1406-1412	immune	substance[77]|abstract[79]	giv[77]|new[79]	_	_
11-16	1413-1423	checkpoint	substance[77]|place|abstract[79]	giv[77]|new|new[79]	_	_
11-17	1424-1434	inhibitors	substance[77]|abstract[79]	giv[77]|new[79]	_	_
11-18	1435-1444	targeting	_	_	_	_
11-19	1445-1455	programmed	abstract[80]	new[80]	appos	11-22[0_80]
11-20	1456-1463	death-1	abstract[80]	new[80]	_	_
11-21	1464-1465	(	_	_	_	_
11-22	1466-1470	PD-1	abstract	giv	_	_
11-23	1471-1472	)	_	_	_	_
11-24	1473-1474	;	_	_	_	_
11-25	1475-1478	and	_	_	_	_
11-26	1479-1490	ramucirumab	substance	new	_	_
11-27	1491-1492	,	_	_	_	_
11-28	1493-1496	the	abstract[83]	new[83]	_	_
11-29	1497-1502	first	abstract[83]	new[83]	_	_
11-30	1503-1519	biomarker-driven	abstract[83]	new[83]	_	_
11-31	1520-1532	therapeutics	abstract[83]	new[83]	_	_
11-32	1533-1541	approved	_	_	_	_
11-33	1542-1545	for	_	_	_	_
11-34	1546-1549	HCC	abstract	giv	ana	11-48
11-35	1550-1554	that	_	_	_	_
11-36	1555-1562	targets	_	_	_	_
11-37	1563-1566	the	substance[87]	new[87]	_	_
11-38	1567-1577	angiogenic	substance[87]	new[87]	_	_
11-39	1578-1586	vascular	substance[87]	new[87]	_	_
11-40	1587-1598	endothelial	substance[87]	new[87]	_	_
11-41	1599-1605	growth	abstract|substance[87]	new|new[87]	coref	15-18
11-42	1606-1612	factor	abstract|substance[87]	new|new[87]	coref	15-17[115_0]
11-43	1613-1621	receptor	substance[87]	new[87]	_	_
11-44	1622-1623	(	_	_	_	_
11-45	1624-1629	VEGFR	object	new	_	_
11-46	1630-1631	)	_	_	_	_
11-47	1632-1633	,	_	_	_	_
11-48	1634-1637	all	abstract	giv	coref	12-7
11-49	1638-1640	of	_	_	_	_
11-50	1641-1646	which	_	_	_	_
11-51	1647-1651	have	_	_	_	_
11-52	1652-1655	not	_	_	_	_
11-53	1656-1660	been	_	_	_	_
11-54	1661-1672	established	_	_	_	_
11-55	1673-1678	until	_	_	_	_
11-56	1679-1682	the	time[90]	new[90]	_	_
11-57	1683-1687	past	time[90]	new[90]	_	_
11-58	1688-1691	few	time[90]	new[90]	_	_
11-59	1692-1697	years	time[90]	new[90]	_	_
11-60	1698-1701	and	_	_	_	_
11-61	1702-1709	require	_	_	_	_
11-62	1710-1717	further	abstract[91]	new[91]	_	_
11-63	1718-1732	investigations	abstract[91]	new[91]	_	_
11-64	1733-1734	.	_	_	_	_

#Text=So far , treatment outcomes for HCC are far from satisfactory , with a 5-year survival rate of only ~18 % .
12-1	1735-1737	So	_	_	_	_
12-2	1738-1741	far	_	_	_	_
12-3	1742-1743	,	_	_	_	_
12-4	1744-1753	treatment	abstract|abstract[93]	new|new[93]	coref|coref	22-12[190_0]|22-12[190_0]
12-5	1754-1762	outcomes	abstract[93]	new[93]	_	_
12-6	1763-1766	for	abstract[93]	new[93]	_	_
12-7	1767-1770	HCC	abstract[93]|abstract	new[93]|giv	coref	13-15
12-8	1771-1774	are	_	_	_	_
12-9	1775-1778	far	_	_	_	_
12-10	1779-1783	from	_	_	_	_
12-11	1784-1796	satisfactory	_	_	_	_
12-12	1797-1798	,	_	_	_	_
12-13	1799-1803	with	_	_	_	_
12-14	1804-1805	a	abstract[96]	new[96]	_	_
12-15	1806-1812	5-year	abstract[96]	new[96]	_	_
12-16	1813-1821	survival	event|abstract[96]	giv|new[96]	_	_
12-17	1822-1826	rate	abstract[96]	new[96]	_	_
12-18	1827-1829	of	abstract[96]	new[96]	_	_
12-19	1830-1834	only	abstract[96]|quantity[97]	new[96]|giv[97]	_	_
12-20	1835-1838	~18	abstract[96]|quantity[97]	new[96]|giv[97]	_	_
12-21	1839-1840	%	abstract[96]|quantity[97]	new[96]|giv[97]	_	_
12-22	1841-1842	.	_	_	_	_

#Text=Evidently , there is an urgent need to develop more effective therapeutic strategies in HCC .
13-1	1843-1852	Evidently	_	_	_	_
13-2	1853-1854	,	_	_	_	_
13-3	1855-1860	there	_	_	_	_
13-4	1861-1863	is	_	_	_	_
13-5	1864-1866	an	abstract[98]	new[98]	_	_
13-6	1867-1873	urgent	abstract[98]	new[98]	_	_
13-7	1874-1878	need	abstract[98]	new[98]	_	_
13-8	1879-1881	to	_	_	_	_
13-9	1882-1889	develop	_	_	_	_
13-10	1890-1894	more	abstract[99]	new[99]	_	_
13-11	1895-1904	effective	abstract[99]	new[99]	_	_
13-12	1905-1916	therapeutic	abstract[99]	new[99]	_	_
13-13	1917-1927	strategies	abstract[99]	new[99]	_	_
13-14	1928-1930	in	abstract[99]	new[99]	_	_
13-15	1931-1934	HCC	abstract[99]|abstract	new[99]|giv	coref	14-20[105_0]
13-16	1935-1936	.	_	_	_	_

#Text=Signal transducer and activator of transcription 3 ( STAT3 ) has recently emerged as a potential therapeutic target for HCC due to its crucial roles in oncogenesis .
14-1	1937-1943	Signal	person[101]	new[101]	_	_
14-2	1944-1954	transducer	person[101]	new[101]	_	_
14-3	1955-1958	and	_	_	_	_
14-4	1959-1968	activator	place[102]	new[102]	_	_
14-5	1969-1971	of	place[102]	new[102]	_	_
14-6	1972-1985	transcription	place[102]|abstract[103]	new[102]|new[103]	_	_
14-7	1986-1987	3	place[102]|abstract[103]	new[102]|new[103]	_	_
14-8	1988-1989	(	place[102]|abstract[103]	new[102]|new[103]	_	_
14-9	1990-1995	STAT3	place[102]|abstract[103]|abstract	new[102]|new[103]|new	coref	15-1
14-10	1996-1997	)	place[102]|abstract[103]	new[102]|new[103]	_	_
14-11	1998-2001	has	_	_	_	_
14-12	2002-2010	recently	_	_	_	_
14-13	2011-2018	emerged	_	_	_	_
14-14	2019-2021	as	_	_	_	_
14-15	2022-2023	a	_	_	_	_
14-16	2024-2033	potential	_	_	_	_
14-17	2034-2045	therapeutic	_	_	_	_
14-18	2046-2052	target	_	_	_	_
14-19	2053-2056	for	_	_	_	_
14-20	2057-2060	HCC	abstract[105]	giv[105]	ana	14-23[0_105]
14-21	2061-2064	due	abstract[105]	giv[105]	_	_
14-22	2065-2067	to	_	_	_	_
14-23	2068-2071	its	abstract|abstract[107]	giv|new[107]	coref|coref|coref|coref	19-13[171_107]|20-8|19-13[171_107]|20-8
14-24	2072-2079	crucial	abstract[107]	new[107]	_	_
14-25	2080-2085	roles	abstract[107]	new[107]	_	_
14-26	2086-2088	in	abstract[107]	new[107]	_	_
14-27	2089-2100	oncogenesis	abstract[107]|abstract	new[107]|new	_	_
14-28	2101-2102	.	_	_	_	_

#Text=STAT3 was initially determined to control acute-phase genes in response to interleukin-6 ( IL-6 ) and epidermal growth factor ( EGF ) during inflammation .
15-1	2103-2108	STAT3	abstract	giv	coref	19-7
15-2	2109-2112	was	_	_	_	_
15-3	2113-2122	initially	_	_	_	_
15-4	2123-2133	determined	_	_	_	_
15-5	2134-2136	to	_	_	_	_
15-6	2137-2144	control	_	_	_	_
15-7	2145-2156	acute-phase	abstract[110]	new[110]	_	_
15-8	2157-2162	genes	abstract[110]	new[110]	_	_
15-9	2163-2165	in	_	_	_	_
15-10	2166-2174	response	abstract	new	_	_
15-11	2175-2177	to	_	_	_	_
15-12	2178-2191	interleukin-6	abstract	new	appos	15-14
15-13	2192-2193	(	_	_	_	_
15-14	2194-2198	IL-6	abstract	giv	_	_
15-15	2199-2200	)	_	_	_	_
15-16	2201-2204	and	_	_	_	_
15-17	2205-2214	epidermal	abstract[115]	giv[115]	appos	15-21[0_115]
15-18	2215-2221	growth	abstract|abstract[115]	giv|giv[115]	coref	19-21
15-19	2222-2228	factor	abstract[115]	giv[115]	_	_
15-20	2229-2230	(	_	_	_	_
15-21	2231-2234	EGF	abstract	giv	_	_
15-22	2235-2236	)	_	_	_	_
15-23	2237-2243	during	_	_	_	_
15-24	2244-2256	inflammation	abstract	new	ana	16-1
15-25	2257-2258	.	_	_	_	_

#Text=It belongs to the STAT family of cytoplasmic transcription factors that mediate signal transduction from the plasma membrane to the nucleus in various cellular activities .
16-1	2259-2261	It	abstract	giv	_	_
16-2	2262-2269	belongs	_	_	_	_
16-3	2270-2272	to	_	_	_	_
16-4	2273-2276	the	abstract[120]	new[120]	coref	17-1[128_120]
16-5	2277-2281	STAT	person|abstract[120]	new|new[120]	_	_
16-6	2282-2288	family	abstract[120]	new[120]	_	_
16-7	2289-2291	of	abstract[120]	new[120]	_	_
16-8	2292-2303	cytoplasmic	abstract[120]|abstract[121]	new[120]|new[121]	_	_
16-9	2304-2317	transcription	abstract[120]|abstract[121]	new[120]|new[121]	_	_
16-10	2318-2325	factors	abstract[120]|abstract[121]	new[120]|new[121]	_	_
16-11	2326-2330	that	_	_	_	_
16-12	2331-2338	mediate	_	_	_	_
16-13	2339-2345	signal	abstract|event[123]	new|new[123]	_	_
16-14	2346-2358	transduction	event[123]	new[123]	_	_
16-15	2359-2363	from	_	_	_	_
16-16	2364-2367	the	place[125]	new[125]	_	_
16-17	2368-2374	plasma	abstract|place[125]	new|new[125]	_	_
16-18	2375-2383	membrane	place[125]	new[125]	_	_
16-19	2384-2386	to	place[125]	new[125]	_	_
16-20	2387-2390	the	place[125]|place[126]	new[125]|new[126]	_	_
16-21	2391-2398	nucleus	place[125]|place[126]	new[125]|new[126]	_	_
16-22	2399-2401	in	place[125]|place[126]	new[125]|new[126]	_	_
16-23	2402-2409	various	place[125]|place[126]|abstract[127]	new[125]|new[126]|new[127]	_	_
16-24	2410-2418	cellular	place[125]|place[126]|abstract[127]	new[125]|new[126]|new[127]	_	_
16-25	2419-2429	activities	place[125]|place[126]|abstract[127]	new[125]|new[126]|new[127]	_	_
16-26	2430-2431	.	_	_	_	_

#Text=The STAT family comprises seven members : STAT1 , 2 , 3 , 4 , 5a , 5b and 6 .
17-1	2432-2435	The	abstract[128]	giv[128]	ana	18-7[0_128]
17-2	2436-2440	STAT	abstract[128]	giv[128]	_	_
17-3	2441-2447	family	abstract[128]	giv[128]	_	_
17-4	2448-2457	comprises	_	_	_	_
17-5	2458-2463	seven	abstract[129]	new[129]	ana	18-3[0_129]
17-6	2464-2471	members	abstract[129]	new[129]	_	_
17-7	2472-2473	:	_	_	_	_
17-8	2474-2479	STAT1	abstract[130]	new[130]	ana	18-1[132_130]
17-9	2480-2481	,	abstract[130]	new[130]	_	_
17-10	2482-2483	2	abstract[130]	new[130]	_	_
17-11	2484-2485	,	_	_	_	_
17-12	2486-2487	3	_	_	_	_
17-13	2488-2489	,	_	_	_	_
17-14	2490-2491	4	quantity	new	_	_
17-15	2492-2493	,	_	_	_	_
17-16	2494-2496	5a	_	_	_	_
17-17	2497-2498	,	_	_	_	_
17-18	2499-2501	5b	_	_	_	_
17-19	2502-2505	and	_	_	_	_
17-20	2506-2507	6	_	_	_	_
17-21	2508-2509	.	_	_	_	_

#Text=Each of them consists of ( i ) an N-terminal domain for oligomerization , ( ii ) a coiled-coil domain for interaction with regulatory proteins , ( iii ) a DNA-binding domain for recognition of specific DNA sequences , ( iv ) a Src homology-2 ( SH2 ) domain that triggers phosphorylation and dimerization after docking to phosphorylated receptors and ( iv ) a C-terminal transactivation domain with specific tyrosine ( Y ) ( present in all STATs ) and serine ( S ) residues ( absent in STAT2 and 6 ) that are phosphorylated upon transcriptional activation .
18-1	2510-2514	Each	abstract[132]	giv[132]	_	_
18-2	2515-2517	of	abstract[132]	giv[132]	_	_
18-3	2518-2522	them	abstract[132]|abstract	giv[132]|giv	_	_
18-4	2523-2531	consists	_	_	_	_
18-5	2532-2534	of	_	_	_	_
18-6	2535-2536	(	_	_	_	_
18-7	2537-2538	i	abstract	giv	_	_
18-8	2539-2540	)	_	_	_	_
18-9	2541-2543	an	place[135]	new[135]	coref	18-30[142_135]
18-10	2544-2554	N-terminal	place[135]	new[135]	_	_
18-11	2555-2561	domain	place[135]	new[135]	_	_
18-12	2562-2565	for	place[135]	new[135]	_	_
18-13	2566-2581	oligomerization	place[135]|abstract	new[135]|new	appos	18-16
18-14	2582-2583	,	_	_	_	_
18-15	2584-2585	(	_	_	_	_
18-16	2586-2588	ii	abstract	giv	_	_
18-17	2589-2590	)	_	_	_	_
18-18	2591-2592	a	place[138]	new[138]	_	_
18-19	2593-2604	coiled-coil	place[138]	new[138]	_	_
18-20	2605-2611	domain	place[138]	new[138]	_	_
18-21	2612-2615	for	place[138]	new[138]	_	_
18-22	2616-2627	interaction	place[138]|abstract[139]	new[138]|new[139]	_	_
18-23	2628-2632	with	place[138]|abstract[139]	new[138]|new[139]	_	_
18-24	2633-2643	regulatory	place[138]|abstract[139]|abstract[140]	new[138]|new[139]|new[140]	appos	18-28[0_140]
18-25	2644-2652	proteins	place[138]|abstract[139]|abstract[140]	new[138]|new[139]|new[140]	_	_
18-26	2653-2654	,	place[138]|abstract[139]	new[138]|new[139]	_	_
18-27	2655-2656	(	place[138]|abstract[139]	new[138]|new[139]	_	_
18-28	2657-2660	iii	place[138]|abstract[139]|abstract	new[138]|new[139]|giv	_	_
18-29	2661-2662	)	place[138]|abstract[139]	new[138]|new[139]	_	_
18-30	2663-2664	a	place[138]|abstract[139]|place[142]	new[138]|new[139]|giv[142]	coref	18-49[0_142]
18-31	2665-2676	DNA-binding	place[138]|abstract[139]|place[142]	new[138]|new[139]|giv[142]	_	_
18-32	2677-2683	domain	place[138]|abstract[139]|place[142]	new[138]|new[139]|giv[142]	_	_
18-33	2684-2687	for	place[138]|abstract[139]|place[142]	new[138]|new[139]|giv[142]	_	_
18-34	2688-2699	recognition	place[138]|abstract[139]|place[142]|event[143]	new[138]|new[139]|giv[142]|new[143]	_	_
18-35	2700-2702	of	place[138]|abstract[139]|place[142]|event[143]	new[138]|new[139]|giv[142]|new[143]	_	_
18-36	2703-2711	specific	place[138]|abstract[139]|place[142]|event[143]|abstract[145]	new[138]|new[139]|giv[142]|new[143]|new[145]	_	_
18-37	2712-2715	DNA	place[138]|abstract[139]|place[142]|event[143]|abstract|abstract[145]	new[138]|new[139]|giv[142]|new[143]|new|new[145]	_	_
18-38	2716-2725	sequences	place[138]|abstract[139]|place[142]|event[143]|abstract[145]	new[138]|new[139]|giv[142]|new[143]|new[145]	_	_
18-39	2726-2727	,	_	_	_	_
18-40	2728-2729	(	_	_	_	_
18-41	2730-2732	iv	person	new	appos	18-62
18-42	2733-2734	)	_	_	_	_
18-43	2735-2736	a	abstract[148]	new[148]	appos	18-47[0_148]
18-44	2737-2740	Src	abstract|abstract[148]	new|new[148]	_	_
18-45	2741-2751	homology-2	abstract[148]	new[148]	_	_
18-46	2752-2753	(	_	_	_	_
18-47	2754-2757	SH2	abstract	giv	_	_
18-48	2758-2759	)	_	_	_	_
18-49	2760-2766	domain	place	giv	coref	18-64[156_0]
18-50	2767-2771	that	_	_	_	_
18-51	2772-2780	triggers	_	_	_	_
18-52	2781-2796	phosphorylation	event	new	_	_
18-53	2797-2800	and	_	_	_	_
18-54	2801-2813	dimerization	event	new	_	_
18-55	2814-2819	after	_	_	_	_
18-56	2820-2827	docking	_	_	_	_
18-57	2828-2830	to	_	_	_	_
18-58	2831-2845	phosphorylated	substance[153]	new[153]	_	_
18-59	2846-2855	receptors	substance[153]	new[153]	_	_
18-60	2856-2859	and	_	_	_	_
18-61	2860-2861	(	_	_	_	_
18-62	2862-2864	iv	person	giv	_	_
18-63	2865-2866	)	_	_	_	_
18-64	2867-2868	a	place[156]	giv[156]	_	_
18-65	2869-2879	C-terminal	place[156]	giv[156]	_	_
18-66	2880-2895	transactivation	abstract|place[156]	new|giv[156]	_	_
18-67	2896-2902	domain	place[156]	giv[156]	_	_
18-68	2903-2907	with	place[156]	giv[156]	_	_
18-69	2908-2916	specific	place[156]|abstract[157]	giv[156]|new[157]	appos	18-72[0_157]
18-70	2917-2925	tyrosine	place[156]|abstract[157]	giv[156]|new[157]	_	_
18-71	2926-2927	(	place[156]	giv[156]	_	_
18-72	2928-2929	Y	place[156]|abstract	giv[156]|giv	_	_
18-73	2930-2931	)	place[156]	giv[156]	_	_
18-74	2932-2933	(	place[156]	giv[156]	_	_
18-75	2934-2941	present	place[156]	giv[156]	_	_
18-76	2942-2944	in	place[156]	giv[156]	_	_
18-77	2945-2948	all	place[156]|object[159]	giv[156]|new[159]	_	_
18-78	2949-2954	STATs	place[156]|object[159]	giv[156]|new[159]	_	_
18-79	2955-2956	)	place[156]	giv[156]	_	_
18-80	2957-2960	and	place[156]	giv[156]	_	_
18-81	2961-2967	serine	place[156]|substance|abstract[162]	giv[156]|new|new[162]	_	_
18-82	2968-2969	(	place[156]|abstract[162]	giv[156]|new[162]	_	_
18-83	2970-2971	S	place[156]|person|abstract[162]	giv[156]|new|new[162]	_	_
18-84	2972-2973	)	place[156]|abstract[162]	giv[156]|new[162]	_	_
18-85	2974-2982	residues	place[156]|abstract[162]	giv[156]|new[162]	_	_
18-86	2983-2984	(	_	_	_	_
18-87	2985-2991	absent	_	_	_	_
18-88	2992-2994	in	_	_	_	_
18-89	2995-3000	STAT2	abstract	new	_	_
18-90	3001-3004	and	_	_	_	_
18-91	3005-3006	6	quantity	new	_	_
18-92	3007-3008	)	_	_	_	_
18-93	3009-3013	that	_	_	_	_
18-94	3014-3017	are	_	_	_	_
18-95	3018-3032	phosphorylated	_	_	_	_
18-96	3033-3037	upon	_	_	_	_
18-97	3038-3053	transcriptional	event[165]	new[165]	_	_
18-98	3054-3064	activation	event[165]	new[165]	_	_
18-99	3065-3066	.	_	_	_	_

#Text=Intensive investigation has been done on STAT3 since its discovery , revealing its physiological roles in early embryonic development , growth and differentiation of various adult tissues .
19-1	3067-3076	Intensive	abstract[166]	new[166]	_	_
19-2	3077-3090	investigation	abstract[166]	new[166]	_	_
19-3	3091-3094	has	_	_	_	_
19-4	3095-3099	been	_	_	_	_
19-5	3100-3104	done	_	_	_	_
19-6	3105-3107	on	_	_	_	_
19-7	3108-3113	STAT3	abstract	giv	ana	19-9
19-8	3114-3119	since	_	_	_	_
19-9	3120-3123	its	abstract|abstract[169]	giv|new[169]	ana|ana	19-13|19-13
19-10	3124-3133	discovery	abstract[169]	new[169]	_	_
19-11	3134-3135	,	_	_	_	_
19-12	3136-3145	revealing	_	_	_	_
19-13	3146-3149	its	abstract|abstract[171]	giv|giv[171]	coref|coref|coref|coref	20-4[177_171]|21-4|20-4[177_171]|21-4
19-14	3150-3163	physiological	abstract[171]	giv[171]	_	_
19-15	3164-3169	roles	abstract[171]	giv[171]	_	_
19-16	3170-3172	in	_	_	_	_
19-17	3173-3178	early	abstract[172]	new[172]	coref	23-15[196_172]
19-18	3179-3188	embryonic	abstract[172]	new[172]	_	_
19-19	3189-3200	development	abstract[172]	new[172]	_	_
19-20	3201-3202	,	_	_	_	_
19-21	3203-3209	growth	event	giv	ana	20-4
19-22	3210-3213	and	_	_	_	_
19-23	3214-3229	differentiation	event[174]	new[174]	_	_
19-24	3230-3232	of	event[174]	new[174]	_	_
19-25	3233-3240	various	event[174]|object[175]	new[174]|new[175]	_	_
19-26	3241-3246	adult	event[174]|object[175]	new[174]|new[175]	_	_
19-27	3247-3254	tissues	event[174]|object[175]	new[174]|new[175]	_	_
19-28	3255-3256	.	_	_	_	_

#Text=In addition , its pathogenic roles in cancer initiation , progression , metastasis , chemoresistance and immunoevasion have been uncovered .
20-1	3257-3259	In	_	_	_	_
20-2	3260-3268	addition	_	_	_	_
20-3	3269-3270	,	_	_	_	_
20-4	3271-3274	its	event|abstract[177]	giv|giv[177]	coref|coref	23-7[193_177]|23-7[193_177]
20-5	3275-3285	pathogenic	abstract[177]	giv[177]	_	_
20-6	3286-3291	roles	abstract[177]	giv[177]	_	_
20-7	3292-3294	in	abstract[177]	giv[177]	_	_
20-8	3295-3301	cancer	abstract[177]|abstract|abstract[179]	giv[177]|giv|new[179]	coref|coref	22-12|22-12
20-9	3302-3312	initiation	abstract[177]|abstract[179]	giv[177]|new[179]	_	_
20-10	3313-3314	,	abstract[177]	giv[177]	_	_
20-11	3315-3326	progression	abstract[177]|event	giv[177]|new	_	_
20-12	3327-3328	,	abstract[177]	giv[177]	_	_
20-13	3329-3339	metastasis	abstract[177]|abstract	giv[177]|new	_	_
20-14	3340-3341	,	abstract[177]	giv[177]	_	_
20-15	3342-3357	chemoresistance	abstract[177]|abstract	giv[177]|new	_	_
20-16	3358-3361	and	abstract[177]	giv[177]	_	_
20-17	3362-3375	immunoevasion	abstract[177]|abstract	giv[177]|new	_	_
20-18	3376-3380	have	_	_	_	_
20-19	3381-3385	been	_	_	_	_
20-20	3386-3395	uncovered	_	_	_	_
20-21	3396-3397	.	_	_	_	_

#Text=To date , STAT3 is widely recognized as an oncogenic factor in diverse human cancers .
21-1	3398-3400	To	_	_	_	_
21-2	3401-3405	date	time	new	_	_
21-3	3406-3407	,	_	_	_	_
21-4	3408-3413	STAT3	abstract	giv	coref	22-4
21-5	3414-3416	is	_	_	_	_
21-6	3417-3423	widely	_	_	_	_
21-7	3424-3434	recognized	_	_	_	_
21-8	3435-3437	as	_	_	_	_
21-9	3438-3440	an	_	_	_	_
21-10	3441-3450	oncogenic	_	_	_	_
21-11	3451-3457	factor	_	_	_	_
21-12	3458-3460	in	_	_	_	_
21-13	3461-3468	diverse	abstract[186]	new[186]	_	_
21-14	3469-3474	human	abstract[186]	new[186]	_	_
21-15	3475-3482	cancers	abstract[186]	new[186]	_	_
21-16	3483-3484	.	_	_	_	_

#Text=Therefore , targeting STAT3 might be an attractive therapeutic strategy for HCC treatment .
22-1	3485-3494	Therefore	_	_	_	_
22-2	3495-3496	,	_	_	_	_
22-3	3497-3506	targeting	_	_	_	_
22-4	3507-3512	STAT3	abstract	giv	coref	23-11[194_0]
22-5	3513-3518	might	_	_	_	_
22-6	3519-3521	be	_	_	_	_
22-7	3522-3524	an	abstract[188]	new[188]	_	_
22-8	3525-3535	attractive	abstract[188]	new[188]	_	_
22-9	3536-3547	therapeutic	abstract[188]	new[188]	_	_
22-10	3548-3556	strategy	abstract[188]	new[188]	_	_
22-11	3557-3560	for	abstract[188]	new[188]	_	_
22-12	3561-3564	HCC	abstract[188]|abstract|abstract[190]	new[188]|giv|giv[190]	coref|coref	23-13|23-13
22-13	3565-3574	treatment	abstract[188]|abstract[190]	new[188]|giv[190]	_	_
22-14	3575-3576	.	_	_	_	_

#Text=In this review , we summarize the oncogenic roles of STAT3 in HCC and the current clinical development of STAT3-targeted therapeutics .
23-1	3577-3579	In	_	_	_	_
23-2	3580-3584	this	abstract[191]	new[191]	_	_
23-3	3585-3591	review	abstract[191]	new[191]	_	_
23-4	3592-3593	,	_	_	_	_
23-5	3594-3596	we	person	acc	_	_
23-6	3597-3606	summarize	_	_	_	_
23-7	3607-3610	the	abstract[193]	giv[193]	_	_
23-8	3611-3620	oncogenic	abstract[193]	giv[193]	_	_
23-9	3621-3626	roles	abstract[193]	giv[193]	_	_
23-10	3627-3629	of	abstract[193]	giv[193]	_	_
23-11	3630-3635	STAT3	abstract[193]|abstract[194]	giv[193]|giv[194]	_	_
23-12	3636-3638	in	abstract[193]|abstract[194]	giv[193]|giv[194]	_	_
23-13	3639-3642	HCC	abstract[193]|abstract[194]|object	giv[193]|giv[194]|giv	_	_
23-14	3643-3646	and	abstract[193]	giv[193]	_	_
23-15	3647-3650	the	abstract[193]|abstract[196]	giv[193]|giv[196]	_	_
23-16	3651-3658	current	abstract[193]|abstract[196]	giv[193]|giv[196]	_	_
23-17	3659-3667	clinical	abstract[193]|abstract[196]	giv[193]|giv[196]	_	_
23-18	3668-3679	development	abstract[193]|abstract[196]	giv[193]|giv[196]	_	_
23-19	3680-3682	of	abstract[193]|abstract[196]	giv[193]|giv[196]	_	_
23-20	3683-3697	STAT3-targeted	abstract[193]|abstract[196]|event|abstract[198]	giv[193]|giv[196]|new|new[198]	_	_
23-21	3698-3710	therapeutics	abstract[193]|abstract[196]|abstract[198]	giv[193]|giv[196]|new[198]	_	_
23-22	3711-3712	.	_	_	_	_
